Laís Calazans Menescal Linhares

Ms. Laís Calazans Menescal Linhares

Universidade Estadual Paulista "Julho Mesquita Filho" - UNESP
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
ANAndrigo Barboza de Nardi
Andrigo Barboza de Nardi
RHRodrigo Dos Santos Horta
Rodrigo Dos Santos Horta
Carlos Eduardo Fonseca-AlvesCarlos Eduardo Fonseca-Alves
Carlos Eduardo Fonseca-Alves
FPFelipe Noleto de Paiva
Felipe Noleto de Paiva
Laís Calazans Menescal LinharesLaís Calazans Menescal Linhares
Laís Calazans Menescal Linhares
MDMaria Dagli
Maria Dagli
Mast cell tumors (MCTs) are hematopoietic neoplasms composed of mast cells. It is highly common in dogs and is extremely important in the veterinary oncology field. It represents the third most common tumor subtype, and is the most common malignant skin tumor in dogs, corresponding to 11% of skin cancer cases. The objective of this critical review was to present the report of the 2nd Consensus meeting on the Diagnosis, Prognosis, and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors, which was organized by the Brazilian Association of Veterinary Oncology (ABROVET) in August 2021. The most recent information on cutaneous and subcutaneous mast cell tumors in dogs is presented and discussed.

29 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ANAndrigo Barboza de Nardi
Andrigo Barboza de Nardi
CMCRISTINA MASSOCO
CRISTINA MASSOCO
Carlos Eduardo Fonseca-AlvesCarlos Eduardo Fonseca-Alves
Carlos Eduardo Fonseca-Alves
FPFelipe Noleto de Paiva
Felipe Noleto de Paiva
Laís Calazans Menescal LinharesLaís Calazans Menescal Linhares
Laís Calazans Menescal Linhares
MDMaria Dagli
Maria Dagli
Hemangiosarcoma is a mesenchymal neoplasm originating in the endothelial cells of blood vessels; they can be classified as non-visceral and visceral types. Non-visceral hemangiosarcomas can affect the skin, subcutaneous tissues, and muscle tissues; visceral hemangiosarcomas can affect the spleen, liver, heart, lungs, kidneys, oral cavity, bones, bladder, uterus, tongue, and retroperitoneum. Among domestic species, dogs are most affected by cutaneous HSA. Cutaneous HSA represents approximately 14% of all HSA diagnosed in this species and less than 5% of dermal tumors, according to North American studies. However, Brazilian epidemiological data demonstrate a higher prevalence, which may represent 27 to 80% of all canine HSAs and 13.9% of all skin neoplasms diagnosed in this species. Cutaneous HSA most commonly affects middle-aged to elderly dogs (between 8 and 15 years old), with no gender predisposition for either the actinic or non-actinic forms. The higher prevalence of cutaneous HSA in some canine breeds is related to lower protection from solar radiation, as low skin pigmentation and hair coverage lead to greater sun exposure. Actinic changes, such as solar dermatosis, are frequent in these patients, confirming the influence of solar radiation on the development of this neoplasm. There are multiple clinical manifestations of hemangiosarcoma in canines. The diagnostic approach and staging classification of cutaneous HSAs are similar between the different subtypes. The definitive diagnosis is obtained through histopathological analysis of incisional or excisional biopsies. Cytology can be used as a presurgical screening test; however, it has little diagnostic utility in cases of HSA because there is a high risk of blood contamination and sample hemodilution. Surgery is generally the treatment of choice for dogs with localized non-visceral HSA without evidence of metastatic disease. Recently, electrochemotherapy (ECT) has emerged as an alternative therapy for the local ablative treatment of different neoplastic types; the use of radiotherapy for the treatment of dogs with cutaneous HSA is uncommon. There is greater consensus in the literature regarding the indications for adjuvant chemotherapy in subcutaneous and muscular HSA; doxorubicin is the most frequently used antineoplastic agent for subcutaneous and muscular subtypes and can be administered alone or in combination with other drugs. Other therapies include antiangiogenic therapy, photodynamic therapy, the association of chemotherapy with the metronomic dose, targeted therapies, and natural products. The benefits of these therapies are presented and discussed. In general, the prognosis of splenic and cardiac HSA is unfavorable. As a challenging neoplasm, studies of new protocols and treatment modalities are necessary to control this aggressive disease.

29 November 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MRMarcelo Monte Mor Rangel
Marcelo Monte Mor Rangel
Laís Calazans Menescal LinharesLaís Calazans Menescal Linhares
Laís Calazans Menescal Linhares
KOKrishna Duro de Oliveira
Krishna Duro de Oliveira
DSDaniela Ota Hisayasu Suzuki
Daniela Ota Hisayasu Suzuki
FMFelipe Horacio Maglietti
Felipe Horacio Maglietti
ANAndrigo Barboza de Nardi
Andrigo Barboza de Nardi
Local treatment of canine urothelial carcinoma (UC) of the bladder is a challenge. More than 90% of the cases invade the muscular layer, more than 50% develop on bladder sites with a difficult surgical approach and often requiring radical surgical procedures. This study aims to evaluate the safety and feasibility of electrochemotherapy (ECT) with intravenous bleomycin (BLM) as a local therapy for bladder UC. This prospective study included 21 dogs with spontaneous bladder UC. Regional/distant metastases and neoplastic infiltration of the serosa was considered the main exclusion criteria. We had no deaths during ECT or in the immediate postoperative period, and no suture dehiscence. Most dogs (19/21) developed mild adverse effects, whereas two dogs developed ureteral stenosis. Complete response (CR) was achieved in 62% of the cases (13/21), while partial response (PR) was achieved in 24% (5/21). The median survival and disease-free survival times were 284 and 270 days, respectively. Overall survival was significantly better in the dogs who achieved a CR. In conclusion, ECT was well-tolerated in dogs with UC, demonstrating its safety and feasibility. These data pave the way for new studies aimed at evaluating the effectiveness of ECT in canine bladder UC as a translational model for human disease.

6 June 2024 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
PDF file
FSFrancielle Fernanda Quirino dos Santos
Francielle Fernanda Quirino dos Santos
Laís Calazans Menescal LinharesLaís Calazans Menescal Linhares
Laís Calazans Menescal Linhares
MRMichelle Do Carmo Pereira Rocha
Michelle Do Carmo Pereira Rocha
KOKrishna Duro de Oliveira
Krishna Duro de Oliveira
MRMarcelo Monte Mor Rangel
Marcelo Monte Mor Rangel
ANAndrigo Barboza de Nardi
Andrigo Barboza de Nardi
Introduction: Squamous cell carcinoma (SCC) is a malignant neoplasm that accounts for approximately 15–25% and 70–80% of all feline cutaneous and oral tumors, respectively. Similar to that in humans, feline SCC can be highly invasive locally; however, its metastasis rate is low. Thus, effective local treatment may be curative for most patients, and includes surgery, electrochemotherapy (ECT), cryosurgery, or a combination of these. However, this neoplasia can manifest more aggressively in some patients, leading to higher recurrence rates. In humans, perineural invasion (PNI) has been described as a relevant tumor dissemination pathway associated with high-risk SCC, resulting in higher recurrence rates, resistance to local treatments, and short survival. However, PNI and its prognostic value have not been described in feline SCC. This study aimed to evaluate the PNI in a feline population with SCC treated with ECT and correlate its presence with the occurrence of local recurrence and other clinical variables.Methods: Twenty-four cats histopathologically diagnosed with SCC between 2013 and 2021 were retrospectively selected from the medical records of the Oncological Center Vet Cancer (São Paulo, SP, Brazil). The inclusion criteria were ECT as the sole therapy, histopathological evaluation of PNI, and absence of distant metastatic disease.Results: The complete response rate was 96% (23/24), and PNI was identified in 33% of the cats (8/24, PNI-positive group), whereas 67% were free of this invasion (16/24, PNI-negative group). All PNI-positive cats developed local recurrence, whereas only five PNI-negative cats experienced recurrence. Local recurrence was significantly associated with PNI (p = 0.03).Discussion: The results of this study are preliminary but promising. The data obtained are the first regarding PNI occurrence in feline SCC and pave the way for further studies, mainly to correlate the PNI with survival data and better define its prognostic value.

14 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Rafael Costa BitencourtRafael Costa Bitencourt
Rafael Costa Bitencourt
GCGiovanna Gabrielle Cruvinel
Giovanna Gabrielle Cruvinel
VTVerônica Maria Teixeira de Castro Terrabuio
Verônica Maria Teixeira de Castro Terrabuio
Laís Calazans Menescal LinharesLaís Calazans Menescal Linhares
Laís Calazans Menescal Linhares
GBGuilherme Andraus Bispo
Guilherme Andraus Bispo
ASAureo Evangelista Santana
Aureo Evangelista Santana
Metronomic chemotherapy (MC) represents an emerging strategy in veterinary oncology which involves the continuous or regularly scheduled administration of low-dose chemotherapeutic agents. Unlike conventional protocols known as maximum tolerated dose chemotherapy (MTDC), MC aims to inhibit tumor angiogenesis, stimulate antitumor immune responses, and delay or prevent the emergence of drug resistance. This review is structured into three key sections: the mechanisms of action of MC; its clinical indications in dogs and cats, particularly for advanced or treatment-resistant cancers; and reported outcomes regarding efficacy, safety, and tolerability. Additionally, we explore the growing interest in combining MC with other therapies, as well as the challenges and future directions for optimizing its use. Current evidence suggests that MC is a promising and well-tolerated option for managing various malignancies—such as carcinomas, sarcomas, and hemangiosarcomas—especially in patients who are not candidates for MTDC.

1 January 2025 in Veterinary Medicine International
Verified
Journal Article
Open access
GBGuilherme Andraus Bispo
Guilherme Andraus Bispo
TOThais Cabral de Oliveira
Thais Cabral de Oliveira
MMMarcela Fernanda Moretti
Marcela Fernanda Moretti
MSMatheus Fujimura Soares
Matheus Fujimura Soares
Laís Calazans Menescal LinharesLaís Calazans Menescal Linhares
Laís Calazans Menescal Linhares
PSPaulo Sergio Patto dos Santo
Paulo Sergio Patto dos Santo
Objective: To evaluate whether intravenous administration of dexmedetomidine alters the electrocardiographic parameters of healthy dogs. Animals: 22 healthy dogs. Study Design: prospective blind clinical trial. Materials and Methods: The dogs underwent electrocardiographic monitoring at two moments: baseline moment (MB), subjected to tranquilization with butorphanol (0.25 mg/kg/IM), and dexmedetomidine moment (MDEX), after 10 min of intravenous administration of dexmedetomidine (bolus of 2 μg/kg, in 2 minutes, followed by continuous infusion at a rate of 2 μg/kg/hour). Results: After intravenous administration of dexmedetomidine, sinus bradycardia predominated. Regarding electrocardiographic parameters, there was a significant increase in the duration of the P wave (44; 51 ms), QRS complex (62; 67 ms), PR interval (95; 126 ms), and QT interval (207; 252 ms) and reduction in the QTc interval (249; 226 ms), without significant change in systolic, mean, and diastolic blood pressure. Conclusion: Intravenous administration of dexmedetomidine in healthy dogs results in increased parasympathetic tone with significant reduction in heart rate and increased conduction time of electrical impulses in the myocardium.